MUC5B and cancer: Subsequently, using an established model involving HIV infection of primary MDMs (2, 26), we chose to move forward with LCL-161 and birinapant to determine whether they sensitize cells to MG1-mediated cell death, as both of these SMAC mimetics are currently in clinical trials for cancer (NCT02098161 and NCT04553692, respectively).